Alzheimer's Disease Neuroimaging Initiative 4

Summary

The Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) is a non-randomized, longitudinal, natural history study designed to validate biomarkers, improve clinical trial design, and advance understanding of Alzheimer's disease across the full disease spectrum. Building on the success of ADNI1, ADNI-GO, ADNI2, and ADNI3, ADNI4 integrates clinical, cognitive, imaging, genetic, and fluid biomarker data to characterize disease progression and predict cognitive decline.

ADNI4 includes both in-clinic and remote cohorts and a small complementary sub-cohort, Together Exploring Aging Minds (TEAM-ADNI), which evaluates community-based recruitment and longitudinal data collection approaches.

Conditions

• Dementia
• Mild Cognitive Impairment
• Alzheimer Disease

Interventions

RADIATION

Neuraceq

Amyloid PET imaging with Florbetaben (Neuraceq) injection

RADIATION

Amyvid

Amyloid PET imaging with Amyvid (Florbetapir) injection

RADIATION

Tauvid

Tau PET imaging with Tauvid (Flortaucipir) injection

RADIATION

MK-6240

Tau PET imaging with MK-6240 injection

RADIATION

NAV4694

Amyloid PET imaging with NAV4694 injection

RADIATION

PI-2620

Tau PET imaging with PI-2620 injection

Sponsors & Collaborators

• Northern California Institute of Research and Education

  collaborator OTHER

• National Institute on Aging (NIA)

  collaborator NIH

• Alzheimer's Therapeutic Research Institute

  collaborator OTHER

• University of Southern California

  lead OTHER

Principal Investigators

• Michael Weiner, MD · University of California, San Francisco

• Paul Aisen, MD · USC Alzheimer's Therapeutic Research Institute (ATRI)

• Ronald Petersen, MD, PHD · Mayo Clinic

Eligibility

Min Age

55 Years

Max Age

90 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2023-06-09

Primary Completion

2027-07-31

Completion

2027-07-31

Countries

• United States
• Canada

Study Locations